Editorial: Genetics of familial hypercholesterolemia: New insight-Volume II.
作者信息
Vuorio Alpo, Ramaswami Uma, Holven Kirsten B
机构信息
Mehiläinen Airport Health Centre, Vantaa, Finland.
Department of Forensic Medicine, University of Helsinki, Helsinki, Finland.
出版信息
Front Genet. 2022 Oct 12;13:1041342. doi: 10.3389/fgene.2022.1041342. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Genetics of familial hypercholesterolemia: New insight-Volume II.社论：家族性高胆固醇血症的遗传学：新见解——第二卷
Front Genet. 2022 Oct 12;13:1041342. doi: 10.3389/fgene.2022.1041342. eCollection 2022.
2
Editorial: Genetics of Familial Hypercholesterolemia: New Insight.社论：家族性高胆固醇血症的遗传学：新见解
Front Genet. 2021 May 6;12:669373. doi: 10.3389/fgene.2021.669373. eCollection 2021.
3
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience.PCSK9 抑制剂治疗杂合子家族性高胆固醇血症的疗效：临床实践经验。
J Clin Lipidol. 2021 Jul-Aug;15(4):584-592. doi: 10.1016/j.jacl.2021.04.011. Epub 2021 May 7.
4
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.载脂蛋白(a)表型决定了潜在家族性高胆固醇血症患者脂蛋白(a)和前蛋白转化酶枯草溶菌素/克那霉 9 水平的相关性。
Atherosclerosis. 2018 Oct;277:477-482. doi: 10.1016/j.atherosclerosis.2018.08.011.
5
New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.新型 LDL 胆固醇降低治疗方法：药理学、临床试验及与急性冠脉综合征的相关性。
Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8.
6
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.伴有前蛋白转化酶枯草溶菌素9型（PCSK9）功能获得性突变的家族性高胆固醇血症中的脂蛋白（a）
Circ J. 2016;80(2):512-8. doi: 10.1253/circj.CJ-15-0999. Epub 2015 Dec 2.
7
8
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.以 PCSK9 为靶点，降低低密度脂蛋白胆固醇：一种有前途的新机制。
Pharmacol Ther. 2016 Aug;164:183-94. doi: 10.1016/j.pharmthera.2016.04.011. Epub 2016 Apr 29.
9
Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?载脂蛋白 B 单克隆抗体在杂合子家族性高胆固醇血症合并心血管疾病中的应用：PCSK-9 抗体之后还有什么？
Eur J Prev Cardiol. 2017 Sep;24(14):1528-1531. doi: 10.1177/2047487317712419. Epub 2017 May 30.
10
PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂：用于治疗高胆固醇血症的单克隆抗体。
Drugs Today (Barc). 2016 Mar;52(3):183-92. doi: 10.1358/dot.2016.52.3.2440527.
本文引用的文献
1
Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations.欧洲儿童家族性高胆固醇血症筛查：公共政策背景与建议
Eur J Prev Cardiol. 2022 Dec 21;29(18):2301-2311. doi: 10.1093/eurjpc/zwac200.
2
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.脂蛋白(a)与动脉粥样硬化性心血管疾病及主动脉瓣狭窄：欧洲动脉粥样硬化学会共识声明。
Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361.
3
Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a).对家族性高胆固醇血症和脂蛋白(a)升高的先证者亲属进行级联检测升高的脂蛋白(a)。
Atherosclerosis. 2022 May;349:219-226. doi: 10.1016/j.atherosclerosis.2021.11.004. Epub 2021 Nov 12.
4
Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition.家族性高胆固醇血症与2019冠状病毒病：一种危险但可治疗的血管病变状况。
Atheroscler Plus. 2021 Sep;43:3-6. doi: 10.1016/j.athplu.2021.08.001. Epub 2021 Aug 8.
5
COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD.伴有或不伴有动脉粥样硬化性心血管疾病（ASCVD）的家族性高胆固醇血症患者中与COVID-19相关的心肌梗死风险
Am J Prev Cardiol. 2021 May 25;7:100197. doi: 10.1016/j.ajpc.2021.100197. eCollection 2021 Sep.
6
Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study.医院获得性严重急性呼吸综合征的长期骨骼和肺部后果：一项前瞻性队列研究的15年随访
Bone Res. 2020 Feb 14;8:8. doi: 10.1038/s41413-020-0084-5. eCollection 2020.
7
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action.降低家族性高胆固醇血症的临床和公共卫生负担：全球行动呼吁。
JAMA Cardiol. 2020 Feb 1;5(2):217-229. doi: 10.1001/jamacardio.2019.5173.
8
Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.家族性高胆固醇血症和脂蛋白(a)升高：双重遗传性风险和新的治疗机会。
J Intern Med. 2020 Jan;287(1):2-18. doi: 10.1111/joim.12981.
9
Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.比较来自八个欧洲国家杂合子家族性高胆固醇血症（FH）患儿的诊断和治疗特征。
Atherosclerosis. 2020 Jan;292:178-187. doi: 10.1016/j.atherosclerosis.2019.11.012. Epub 2019 Nov 15.
10
Statins for children with familial hypercholesterolemia.用于家族性高胆固醇血症儿童的他汀类药物。
Cochrane Database Syst Rev. 2019 Nov 7;2019(11):CD006401. doi: 10.1002/14651858.CD006401.pub5.
Zotero 插件